While EGFR-TKIs and EGFR-TKI plus anti-VEGFR combination therapy are treatment options for advanced EGFRm+ NSCLC, most patients eventually acquire drug resistance and progress to relapse. The gene discussed is KDR; the disease is non-small cell lung carcinoma.